This study is a multicenter, dual-arm and randomized controlled clinical trial. Sixty patients with dilated cardiomyopathy and positive β1-adrenergic receptor autoantibodies were selected and randomly divided into an immunoadsorption group (receiving immunoadsorption therapy) and a control group in a 1:1 ratio. Changes in cardiac function, morphology and clinical outcomes were followed up and compared.
Dilated cardiomyopathy
Presence of anti-β1-adrenergic receptor
Age 18-75 years
LVEF ≤ 40% determined by echocardiography (according to assessment of the local investigators)
ICD implantation < 1 month or CRT/D implantation < 6 months
Heart failure caused by other heart diseases
End-stage heart failure, inability to discontinue intravenously positive inotropic or vasoactive drugs
Expected survival < 1 year